GLP1R and kidney disorder: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become central to this strategy, not only for their potent glucose-lowering properties but also for their ability to reduce body weight, improve lipid profiles, slow the progression of nephropathy, and lower the risk of cardiovascular events [3-6].